newsfilter
← Latest News
GlobeNewswire·

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's activation of p21-induced cell cycle arrestin murine b